Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy
Cytometry Part B: Clinical Cytometry · 2023-05 · 104 (3) · 224-242
DOI: 10.1002/cyto.b.22097 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 02.11.2022. Verfasst von Qi Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Plasma Cells, Neoplasms, Plasma Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Flow cytometry has been indispensable in diagnosing B cell lymphoma and plasma cell neoplasms. The advances in novel multicolor flow cytometry have also made this technology a robust tool for monitoring minimal/measurable residual disease in chronic lymphocytic leukemia and multiple myeloma. However, challenges using conventional gating strategies to isolate neoplastic B or plasma cells are emerging due to the rapidly increasing number of antibody therapeutics targeting single or multiple classic B/plasma cell‐lineage markers, such as CD19, CD20, and CD22 in B cells and CD38 in plasma cells. This review is the first of a two‐part series that summarizes the most current targeted therapies used in B and plasma cell neoplasms and proposes detailed alternative approaches to overcome post‐targeted therapy analysis challenges by flow cytometry. The second review in this series (Chen et al.) focuses on challenges encountered in the use of targeted therapy in precursor B cell neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
ORCID-Profile: Qi Gao
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Gao, Q., Chen, X., Cherian, S., & Roshal, M. (2023). Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry Part B: Clinical Cytometry, 104(3), 224-242. https://doi.org/10.1002/cyto.b.22097
Vancouver
Gao Q, Chen X, Cherian S, Roshal M. Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry Part B: Clinical Cytometry. 2023;104(3):224-242. doi:10.1002/cyto.b.22097
BibTeX
@article{Gao2023,
author = {Gao, Qi and Chen, Xueyan and Cherian, Sindhu and Roshal, Mikhail},
title = {Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2023},
volume = {104},
number = {3},
pages = {224--242},
doi = {10.1002/cyto.b.22097}
}
EUVIMED